State of Art in Antibacterial Susceptibility of Bordetella Pertussis and Antibiotic Treatment of Pertussis

Overview

Journal Infection

Date 1998 Aug 26

PMID 9717684

Citations 3

Authors

J E Hoppe

Affiliations

Soon will be listed here.

Citing Articles

Emerging macrolide resistance in in mainland China: Findings and warning from the global pertussis initiative.

Feng Y, Chiu C, Heininger U, Hozbor D, Tan T, von Konig C Lancet Reg Health West Pac. 2021; 8:100098.

PMID: 34327426 PMC: 8315362. DOI: 10.1016/j.lanwpc.2021.100098.

Neurologic alterations in an HIV adult patient with pertussis: a case report.

Arango-Granados M, Trompa I BMC Infect Dis. 2020; 20(1):471.

PMID: 32615931 PMC: 7330534. DOI: 10.1186/s12879-020-05198-x.

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Mattoo S, Cherry J Clin Microbiol Rev. 2005; 18(2):326-82.

PMID: 15831828 PMC: 1082800. DOI: 10.1128/CMR.18.2.326-382.2005.

References

Granstrom G, Sterner G, Nord C, Granstrom M . Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J Infect Dis. 1987; 155(6):1210-4. DOI: 10.1093/infdis/155.6.1210. View

Appleman M, Hadfield T, Gaines J, Winn R . Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs. Diagn Microbiol Infect Dis. 1987; 8(2):131-3. DOI: 10.1016/0732-8893(87)90162-3. View

Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R . Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr. 1996; 129(5):761-4. DOI: 10.1016/s0022-3476(96)70163-4. View

Sprauer M, Cochi S, Zell E, Sutter R, Mullen J, Englender S . Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am J Dis Child. 1992; 146(2):177-81. DOI: 10.1001/archpedi.1992.02160140043018. View

Lewis K, Saubolle M, Tenover F, Rudinsky M, Barbour S, Cherry J . Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr Infect Dis J. 1995; 14(5):388-91. DOI: 10.1097/00006454-199505000-00010. View

Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K . In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin. Antimicrob Agents Chemother. 1995; 39(11):2544-51. PMC: 162981. DOI: 10.1128/AAC.39.11.2544. View

Hoppe J, Seibert G . In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Antimicrob Agents Chemother. 1996; 40(3):807-8. PMC: 163206. DOI: 10.1128/AAC.40.3.807. View

Hoppe J, Haug A . Antimicrobial susceptibility of Bordetella pertussis (Part I). Infection. 1988; 16(2):126-30. DOI: 10.1007/BF01644321. View

Nakamori Y, Tsuboi E, Narui K, Nakatani T, Nakata K, Sugi H . [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections]. Jpn J Antibiot. 1992; 45(5):539-47. View

10.

De Rose V, Ferrara A, Mangiarotti P, Nonis A, Bertoletti R, Gialdroni Grassi G . Penetration of roxithromycin in bronchial secretions. Int J Clin Pharmacol Res. 1988; 8(2):107-10. View

11.

SWANSON R, Hardy D, Chu D, Shipkowitz N, Clement J . Activity of temafloxacin against respiratory pathogens. Antimicrob Agents Chemother. 1991; 35(3):423-9. PMC: 245026. DOI: 10.1128/AAC.35.3.423. View

12.

Hoppe J . Update of epidemiology, diagnosis, and treatment of pertussis. Eur J Clin Microbiol Infect Dis. 1996; 15(3):189-93. DOI: 10.1007/BF01591352. View

13.

Hoppe J, Tschirner T . Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis. Eur J Clin Microbiol Infect Dis. 1995; 14(9):775-9. DOI: 10.1007/BF01690992. View

14.

Bauernfeind A, Jungwirth R . Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection. 1991; 19(5):353-62. DOI: 10.1007/BF01645369. View

15.

Hoppe J, Muller J . In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins. Antimicrob Agents Chemother. 1990; 34(7):1442-3. PMC: 175997. DOI: 10.1128/AAC.34.7.1442. View

16.

Bauernfeind A, Jungwirth R, Eberlein E, Klesel N, Adam F, Isert D . RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. J Antibiot (Tokyo). 1992; 45(4):505-20. DOI: 10.7164/antibiotics.45.505. View

17.

Miyazaki S, Domon H, Tateda K, Ohno A, Ishii Y, Matsumoto T . In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob Agents Chemother. 1997; 41(11):2582-5. PMC: 164170. DOI: 10.1128/AAC.41.11.2582. View

18.

De Serres G, Boulianne N, Duval B . Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J. 1995; 14(11):969-75. DOI: 10.1097/00006454-199511000-00009. View

19.

Hardy D, Hensey D, Beyer J, Vojtko C, McDonald E, Fernandes P . Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988; 32(11):1710-9. PMC: 175956. DOI: 10.1128/AAC.32.11.1710. View

20.

Hewlett E . Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J. 1997; 16(4 Suppl):S78-84. DOI: 10.1097/00006454-199704001-00002. View